

Amphastar Pharmaceuticals to Present at the 2016 Wells Fargo Healthcare Conference

September 1, 2016

RANCHO CUCAMONGA, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jason Shandell, President will be presenting at the 2016 Wells Fargo Healthcare Conference on Thursday, September 08, 2016 at 2:20 p.m. Eastern Time in Boston, MA.

This presentation will be made available with a live webcast and may be accessed by visiting Amphastar's Pharmaceuticals website at <http://ir.amphastar.com/events.cfm>. This webcast will be available for 90 days following the presentation.

About Amphastar:

Amphastar is a specialty pharmaceutical company established in 1996 that primarily develops, manufactures, markets, and sells generic and proprietary injectable and inhalation products, including products with high technical barriers to market entry. Most of the Company's products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. We currently produce approximately 16 injectable products while we continue to develop a portfolio of generic and branded products that target large markets with high technical barriers to entry. Amphastar's long-standing relationship with the major group purchasing organizations and drug wholesalers in the U.S. enables it to establish significant market share upon the introduction of its new products.

Please visit us online at <http://www.amphastar.com/index.html> for more Company information.

Forward-Looking Statement:

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to the Company's expectations regarding future financial performance, sales and marketing of its products, market size and growth, the timing of FDA filings or approvals, acquisitions and other matters related to its pipeline of product candidates, its internal controls and other future events. These statements are not historical facts but rather are based on Amphastar's historical performance and its current expectations, estimates, and projections regarding Amphastar's business, operations and other similar or related factors. Words such as "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expects," "intends," "plans," "projects," "believes," "estimates," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission. You can locate these reports through the Company's website at <http://ir.amphastar.com> and on the SEC's website at www.sec.gov. Amphastar undertakes no obligation to revise or update information in this press release or the conference call referenced

above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause the Company's expectations to change.

William J. Peters
Chief Financial Officer
(909) 476-3416

Source: Amphastar Pharmaceuticals Inc.